BioCentury
ARTICLE | Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

February 26, 2019 2:01 PM UTC

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.

Invus Opportunities and Flying L Partners co-led the round in collaboration with Falcon Vision. Existing investors New Enterprise Associates and Versant Ventures, as well as new investor Vida Ventures, also participated in the round...